Publika­tionen

Adoptive T-Zell-Therapie mit TCR-modifizierten T-Zellen

Kathrin Davari, Tristan Holland, Laura Prassmayer, Giulia Longinotti, Kenneth P Ganley, Lisa J Pechilis, Iulia Diaconu, Prashant R Nambiar, Michael S Magee, Dolores J Schendel, Daniel Sommermeyer, Christian Ellinger. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy. Journal for ImmunoTherapy of Cancer; 9(3); 25 March 2021; doi: 10.1136/jitc-2020-002035

Publikation

Gary Waanders, Silke Raffegerst, Petra Prinz-Schulz, Maja Buerdek. The T cell therapy field faces preclinical and translational R&D challenges as it targets more complex diseases. Cell & Gene Therapy Insights 2021; 7(1), 71–80; doi: 10.18609/cgti.2021.017

Weitere Informationen

Anja Mösch1,2, Silke Raffegerst2, Manon Weis2, Dolores J. Schendeland Dmitrij Frishman1Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors.  Frontiers in Genetics Review published: 19 November 2019 doi: 10.3389/fgene.2019.01141

1 Department of Bioinformatics, Wissenschaftszentrum Weihenstephan, Technische Universität München, Freising, Germany,
2 Medigene Immunotherapies GmbH, a subsidiary of Medigene AG, Planegg, Germany

Download PDF (2 MB)

Jaravine, V., Raffegerst, S., Schendel, DJ., Frishman, D.  Assessment of cancer and virus antigens for cross-reactivity in human tissues Bioinformatics 2017 Jan 1;33(1):104-111. doi: 10.1093/bioinformatics/btw567.

Weitere Informationen

Schlenker, R., Olguín-Contreras, L., Leisegang, M., Schnappinger, J., Disovic, A., Rühland, S., Nelson, P., Leonhardt, H., Harz, H., Wilde, S., Schendel, D. Uckert, W., Willimsky, G. and Noessner, E. Cancer Research, 2017. Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy

Weitere Informationen

Haase, K., Raffegerst, S., Schendel, D., Frishman, D.   Expitope: a web server for epitope expression. Bioinformatics. 2015 Jun 1;31(11):1854-6. doi: 10.1093/bioinformatics/btv068. 

Weitere Informationen

Obenaus, M., Leitão, C., Leisegang, M., Chen, X., Gavvovidis, I., van der Bruggen, P., Uckert, W., Schendel, D.J. and Blankenstein, T. 2015. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. Nature Biotechnology 33, 402–407 (2015).

Weitere Informationen

Schendel, D.J. and P.D. Greenberg. 2014. The ABC’s of T cell receptor gene therapy. In: Cancer Immunotherapy Meets Oncology (Britten, C.M., Kreiter, S., Diken, M., Rammensee, H.-G., Eds). Pp. 117-126. Springer International Publishing, Switzerland, Heidelberg, Dordrecht, London, New York, 25.05.2014. 

Weitere Informationen

Pinto, S., Sommermeyer, D., Michel, C., Wilde, S., Schendel, D, Uckert, W., Blankenstein T., Kyewski, B. 2014. Mis-initiation of MART-1 transcription in the thymus and biased TCR usage can explain the high frequency of peripheral MART-1 specific T cells. Eur J Immunol. 2014 May 20 [Epub ahead of print].

Weitere Informationen

Schendel, D.J. and Frankenberger, B. 2013. Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity. Oncoimmunology. 2013 Jan 1; 2(1):e22410.

Weitere Informationen

Morgan, R. A., Chinnasamy, N.,  Abate-Daga, D.,  Gross, A., Robbins, P. F.,  Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., Phan, G., Hughes, M. S.,  Kammula, U. S., Miller, A., Hessman, C., Stewart, A., Restifo, R., Quezado, M. M. (+ other members of Pathology staff), Nath, A., Wang, D., Bielekova, B., Wuest, S., Nirmala, A., (+ others, NIMH deep sequencing group), Schendel, D. J., Wilde, S., Mosetter, B., Laurencot, C. and Rosenberg, S. A. 2013. Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 36(2):133-151.

Weitere Informationen

Wilde, S. and D.J., Schendel. 2012. High-quality and high-avidity T cell clones specific for tumor-associated antigens and how to find them. Oncoimmunology. 1(9):1643-1644.

Weitere Informationen

Wilde, S., Sommermeyer, D., Leisegang, M., Frankenberger, B., Mosetter, B., Uckert, W. and D. J. Schendel. 2012. Human antitumor CD8+ T cells producing Th1-polycytokines show superior antigen sensitivity and tumor recognition. J Immunol. 189(2): 598-605.

Weitere Informationen

Wilde, S., Geiger, C., Milosevic, S., Mosetter, B., Eichenlaub, S. and D.J. Schendel. 2012. Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure. Oncoimmunology. 1(2): 129-140.

Weitere Informationen

Leisegang M., Wilde S., Spranger S., Milosevic S., Frankenberger B., Uckert W. and D.J. Schendel. 2010. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J. Clin. Invest. 120 (11): 3869-3877.

Weitere Informationen

Wilde, S., Sommermeyer, D., Frankenberger, B., Schiemann, M., Milosevic, S., Spranger, S., Pohla, H., Uckert, W., Busch, D.H. and D.J. Schendel. 2009. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior anti-tumor activity and higher TCR functional avidity. Blood 114(10): 2131-2139.

Weitere Informationen

Becker, C., Pohla, H., Frankenberger, B., Schüler, T., Assenmacher, M., Schendel, D.J. and Blankenstein, T. 2001. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nat Med.; 7 (10):1159–1162.

Weitere Informationen

Dendritische Zellvakzine

Bigalke I., Eckl J., Solum G., Hønnåshagen K., Skoge L., Fløisand Y., Josefsen D., Sæbøe-Larssen S., Geiger C., Schendel D., Kvalheim G. 2018. Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use

Download PDF (739 KB)

Subklewe M., Geiger C., Lichtenegger F.,  Javorovic M., Kvalheim G., Schendel D.J., Bigalke I. 2014. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunology. 10.1007/s00262-014-1600-5

Download PDF (821 KB)

Lichtenegger, F. S., Mueller, K., Otte, B., Beck, B., Hiddemann, W.,  Schendel, D. J. and M. Subklewe. 2012. CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS One. 7(9): e44266.

Weitere Informationen

Spranger, S., Frankenberger, B. and D. J. Schendel. 2012. NOD/scid IL-2Rgnull mice: a pre-clinical model system to evaluate human dendritic cell-based vaccine strategies in vivo.  J Transl. Med. 10(1): 30. [Epub ahead of print]

Weitere Informationen

Frankenberger, B. and D.J. Schendel. 2012. Third generation dendritic cell vaccines for tumor immunotherapy. Eur. J. Cell Biol. 91(1): 53-58 [Epub 2011 Mar 25]

Weitere Informationen

Beck, B., Dörfel, D., Lichtenegger, F.S., Geiger, C., Lindner, L., Merk, M., Schendel, D.J., and M. Subklewe. 2011. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J. Transl. Med. 9:151 [Epub. Sep. 13]

Weitere Informationen

Spranger, S., Javorovic, M., Bürdek, M., Wilde, S., Mosetter, B., Tippmer, S., Bigalke, I., Geiger, C., Schendel, D.J. and B. Frankenberger. 2010. Generation of T helper-1 polarizing dendritic cells using the Toll-like receptor 7/8 agonist CL075. J. Immunol. 185(1): 738-747. 

Weitere Informationen

Bürdek M., Spranger S., Wilde S., Frankenberger B., Schendel D.J. and C. Geiger. 2010 Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation. J. Transl. Med. 8:90.

Weitere Informationen

Javorovic, M., Wilde, S., Zobywalski, A., Noessner, E., Lennerz, V., Wölfel, T., and D.J. Schendel. 2008. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells. J. Immunother 31(1): 52-62. 

Weitere Informationen

Zobywalski, A., Javorovic, M., Frankenberger, B., Pohla, H., Kremmer, E., Bigalke, I. and D.J. Schendel. 2007. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl Med. 5:18 (highly accessed).

Weitere Informationen